Urologic Health, an Israeli medical device company pioneering non-invasive urodynamics, has successfully closed an $11 million seed financing round. The funding will be used to advance clinical validation, pursue FDA 510(k) regulatory clearance, and support initial commercialization efforts in the United States.
Addressing a Critical Gap in Urological Care
Bladder dysfunction conditions, including overactive bladder, urinary retention, incontinence, and benign prostatic hyperplasia (BPH), affect hundreds of millions of people worldwide and often require ongoing clinical assessment. Current diagnostic tools remain limited by their high invasiveness and discomfort, which frequently leads patients to defer or avoid necessary evaluations.
Urologic Health’s non-invasive niu™ System is designed to address this gap by delivering comprehensive bladder function data without any catheterization, supporting routine, repeatable assessment and longitudinal monitoring of bladder function. The company has completed early feasibility studies demonstrating that the niu System can capture clinically meaningful bladder activity non-invasively.
“Invasive urodynamics remains one of the most significant barriers in modern urological care,” said Adam Yaacov, Co-founder and CEO of Urologic Health. “While treatment options have evolved considerably, the invasive diagnostic process continues to present challenges for patients. Urologic aims to make bladder function assessment easier for clinicians to perform, painless for patients to undergo, and more informative for longitudinal decision-making.”
Investor Participation and Venture Creation Model
The seed round was led by an undisclosed strategic investor, with participation from Edge Medical Ventures, SHD Partners, Longevity Venture Partners, and additional healthcare-focused investors.
Urologic Health was founded and incubated at the MEDX Xelerator venture studio, now known as EdgeLabs, and operates as part of the Edge Medical Ventures portfolio, with operations in the United States and Israel. The company was co-founded by Adam Yaacov and Dr. Noam Omer, who bring expertise in developing innovative medical technologies that advance healthcare through AI-driven insights and data-centric clinical solutions.
Shai Policker, Managing Partner of Edge Medical Ventures and Chairman of Urologic’s board, commented: “Urologic Health was established through our unique venture creation model, which works together with strategic industry partners to identify needs and address them by bringing together talented entrepreneurs to build high-potential medical device companies.” He added, “By combining exceptional engineering talent in Israel with Edge’s operational support, we are able to help companies like Urologic Health move faster through clinical validation, regulatory execution, and early market entry in the United States.”
The niu™ System is not yet approved for sale in the United States and is currently limited to investigational use. The company plans to use the new financing to advance clinical validation, continue product and manufacturing development, and establish its headquarters in Jersey City, New Jersey, in preparation for initial US market entry.
